Systemic Oral Enzymes
in Cancer Therapeutics
from The Doctor's Prescription for Healthy Living - Volume 4, Number 5
NOTE: Although the WOBE-MUGOS® formula -- which
was used in every single one of these trials -- is not yet available in
the United States, it is under evaluation by the Food and Drug Administration
for consideration as an investigational new drug in the area of cancer
theapeutics.
In the meantime, our
advisory board members with experience in cancer therapeutics suggest
that WOBENZYM®N (which is available at health food stores and natural
product supermarkets) can be profitably substituted for WOBE-MUGOS.
Wobenzym N has an
enzyme activity of approximately 900 FIP and WOBE-MUGOS 1200 FIP. From
results of the clinical trials we speculate that the important enzymes
in oncology might be chymotrypsis and papain which are ingredients in
both preparations. However, WOBE-MUGOS contains the highest amount of
chymotrypsin and papain per tablet.
Regarding the concentration
of chymotrypsin activity being part of pancreatin it might be sufficient
to substitute five tablets of WOBE-MUGOS taken three times daily with
ten tablets of Wobenzym N taken three times daily.
Of course, for cancer
treatment, we advise our readers to work with their physician.
Numerous studies worldwide
indicate that systemic oral enzymes can often be used to great advantage
as adjuvant treatment to complement cancer therapeutics. The clinical
experience of leading European oncologists such as Drs. Michael Schedler
and Heinrich Wrba convincingly demonstrates the utility of such preparations
in a wide range of cancers (see The Doctor's Prescription for Healthy
Living, volumes 4.3 and 4.4: 10-11, 18 and 14-15, 20, respectively). What's
more, the National Cancer Institute is now funding a multi-million dollar
study on the use of systemic oral enzymes in treatment of pancreatic cancer
(see also volume 4.3: 10-11, 18).
Systemic oral enzymes
not only benefit overall immunity, they help to reduce the side effects
and complications of chemotherapy and radiation, thus enabling optimum
dosages with minimal adverse consequences and improved therapeutic outcomes.
Enzyme Therapy Inhibits
Matastasis (Spread) of Cancer
For about 30 years, a number of work groups have concerned themselves
with the influence of proteolytic enzymes on metastasis. In the 1960s,
scientists were of the opinion that cancer cell stickiness resulting from
a deficiency in enzymes was responsible for the frequent development of
secondary tumors. This stickiness of the cancer cells was generally recognized
to result from the excessive formation of fibrin.
The close relationship
between fibrin deposits and other types of invasive tissue growth and
metastasis is adequately described in international literature and is
generally accepted. The discovery of substances, known as adhesion molecules,
provided important new impulses for current scientific discussions.
Inflammation also
plays a role in cancer spread. Since the endothelium of tissue with inflammatory
alterations has a thicker layer of specific adhesion molecules, these
are sites where metastasis are more likely to occur. The importance of
chronic progress of inflammation in tumor growth and metastasis has been
demonstrated in studies which verify the influence of anti-inflammatory
therapy on inhibiting metastasis.
Formation of fibrin
on the tumor cell membrane supports this adhesive process and serves as
a protective barrier against tumor cell recognition by the immunological
system. Proteolytic enzymes inhibit both excess fibrin deposition and
inflammation, thus helping to prevent the spread of tumor cells.
Indeed, one of the
most impressive features of clinical trials for patients with multiple
myeloma, breast, stomach, colon and pancreatic cancers, is prolongation
of survival time. This may reflect reduced tendency toward cancer spread.
We've combed through
many of Europe's leading medical journals in order to provide results
for some cancers for which systemic oral enzymes work best.
Multiple Myeloma
Most recently, Dr. Wrba's team has looked at how systemic oral enzymes
help in difficult-to-treat cancers such as multiple myeloma and they are
currently preparing an important paper on prolonging survival among patients
with this usually fatal disease. In fact, the U.S. Food and Drug Administration
has approved investigational new drug status for use of a systemic oral
enzyme preparation (i.e., Wobe-Mugos® from Mucos Pharma GmbH) in treatment
of this cancer. It was found that treatment with Wobe-Mugos® in addition
to conventional chemotherapy prolongs remission times in stage II multiple
myeloma patients and reduces the concentrations of progression markers.
Stomach Cancer
In a large-scale study performed on 5,400 patients with stomach cancer,
Dr. J.P. Kim was able to attain an increase in the five-year survival
rate in more than 50 percent of patients through the administration of
systemic oral enzymes with picibanil (OK-432), an immunomodulatory extract
derived from Streptococcus pyogenes. The enzyme had both an immunoregulatory
effect and inhibited metastasis.
The study impressively
demonstrated the highly improved immune status in patients treated with
the WOBE-MUGOS preparation. The therapy with picibanil and systemic oral
enzymes also improved natural killer cells' ability to destroy cancer
cells.
In another prospective,
randomized, placebo-controlled clinical study, patients receiving adjuvant
therapy with systemic oral enzymes experienced half the rate of death
and recurrency.
Colon Cancer
Dr. A. Sakalova observed the positive efffects of systemic oral enzyme
therapy in the treatment of patients with solid and metastatic colon cancer.
In an open clinical study, 23 patients who had undergone surgery were
subsequently treated with chemotherapy and systemic oral enzymes. During
the observation period of six to thirty months, 64 percent of the patients
were still alive.
Dr. W.D. Blessing
also reported on the success of a complementary therapy with systemic
oral enzymes in treatment of colon cancer. The patients generally survived
longer than two years after the start of the initial therapy when treated
with complementary WOBE-MUGOS therapy. A number of these patients have
already survived for five to twelve years.
Pancreatic Cancer
Drs. Hager and Abel developed a complementary therapeutic concept to patients
with advanced pancreas carcinoma and treated 30 patients.
After beginning the
therapy, 17 patients were completely free of pain within a short time.
All of the other patients claimed to have experienced a substantial to
very substantial reduction in the amount of pain. The general state of
health of the patients improved as well. A clear prolongation in life
expectancy was attained with more than half of the patients enjoying a
prolongation of survival of one to two years or longer.
Gynecological Cancers
Dr. G. Stojanow treated 83 patients with gynecological tumors (cancers
of the cervix, breast, uterus) using a complementary therapy with systemic
oral enzyme therapy. An improved response to the primary therapy was observed,
as well as an improved quality of life and reduced periods of hospitalization.
The observation that systemic oral enzyme therapy clearly inhibits development
of metastasis is especially interesting. Dr. A. Hofmann also reported
on successfu use of systemic enzyme therapy for treatment of inoperable
uterine cancer.
Breast Cancer
Dr. O. Rokitansky and co-investigators performed multiple retrospective
and randomized studies on the complementary application of systemic oral
enzymes in the treatment of breast cancer. Comparing the results of the
retrospectively evaluated findings, the patients receiving complemetary
therapy had higher survival rates free of recurrency.
Ovarian Cancer
Systemic oral enzymes seem to help most in ovarian cancer by addressing
the dose-limiting factors involved in chemotherapy, such as liver toxicity.
In one clinical trial, chemotherapy was followed by five days of intensive
systemic oral enzyme therapy among 59 patients who were treated with chemotherapy
following surgical intervention. Among women receiving the enzyme therapy,
average thrombocyte and lymphocyte count became normalized.
Lymphoma
During recent years, various therapists have reported cases of patients
with T cell lymphomas who have undergone therapy using systemic oral enzymes
which has resulted in a regression of the tumors that has lasted for up
to 10 years. Raul Ahumada, M.D., documented one case in which the state
of health of a 51-year-old man with a typical clinical picture of a T
cell lymphoma in an advanced tumor stage had deteriorated rapidly. The
skin biopsy revealed a lymphatic tumor (T cell lymphoma of the skin).
However, after six months of therapy with systemic oral enzymes, the patient's
symptoms had improved substantially. No cancerous cells, subcutaneous
nodes or tumor remnants could be found. The patient's state of health
had remained stable for the last five years.
How Systemic Oral
Enzymes Inhibit Cancer Spread
Various mechanisms have been discussed as being active in the inhibition
of metastasis by systemic enzyme therapy:
Down regulation of
metastatically relevant adhesion molecules.
Reduction of fibrin-supported adhesion.
Increase in the immunogenicity (mucin, fibrin, inhibitory substances)
of the tumor cells.
Regulation of inflammatory reactions.
Down regulation of metastatically relevant adhesion molecules on the endothelium.
Improvement in immunosurveillance.
Numerous clinical reports and publications demonstrate a positive influence
of systemic oral enzymes on the prophylaxis of metastasis and on the prevention
of recurrency. For all of our reports on systemic oral enzymes and cancer,
visit www.freedompressonline.com.
| 
